Survival of Patients with Small-Cell Lung Cancer Treated at Tertiary Hospitals in the East of Thailand, 2007-2016: A Retrospective Study

• 作者: Annop Kittiwarawut Chokaew Tovanabutra Kittisak Chomprasert Passakorn Wanchaijiraboon Sirentra Wanglikitkoon Sitthi Sukauichai Teerayuth Namkanitsorn Thapana Tangchewinsirikul
• 来源期刊: 肺癌(英文)
• 学科: 医学
• 关键词: SURVIVAL SMALL Cell LUNG CANCER TERTIARY Hospitals Thailand
• 年，卷（期）: 2019,（1）
• 页码范围: 1-14
• 页数: 14页
• 分类号: R73

摘要

Objective:?The objective of the study was to determine the survival of patients?with small-cell lung cancer treated at tertiary hospitals in the East of?Thailand. Materials and methods:?The researchers conducted this retrospective?study by reviewing medical records of patients with small-cell lung cancer?treated at Chonburi Cancer Hospital and Prapokklao Hospital from January?2007 to December 2016 and monitored via follow-up until December?2018. Results:?This study enrolled 54 patients with a median follow-up time?of 8.5 months. The median age of patients was 63 years old. Most patients?were male (83.3%) and had a history of smoking (90.7%), and 31.4% had?clinical superior vena cava obstruction at initial treatment. The Eastern Cooperative?Oncology Group performance status 0-1 was noted for 61.1% of the?study population. Median survival time of patients with limited-stage and extensive-stage small cell lung cancer who received systemic chemotherapy?and/or radiotherapy was 17.01 months (95% CI, 12.01 - 22.01) and 8.14?months (95% CI, 7.19 - 9.10), respectively, and that of patients receiving?supportive care was 2.3 months (95% CI, 0.75 - 4.03). However, the median?survival time of patients with extensive-stage small-cell lung cancer receiving?only palliative chemotherapy was 5.9 months (95% CI, 0.32 - 17.51). Conclusions:?The median survival time of patients with limited-stage small-cell lung?cancer treated in the East of Thailand was comparable to those of landmark?studies;however, the survival of patients with extensive-stage small-cell lung?cancer was shorter than those of Phase III trials. A multidisciplinary team was?necessary to improve the quality of patient care.